Astellas reports promising early results for stem cell eye therapy ASP7317 in age-related disease
read at Endpoints ↗Positive readoutPositive
Astellas announced data from an early-stage trial of ASP7317, a stem cell-derived therapy aimed at an age-related eye condition.
The study showed encouraging signs of efficacy and safety in most participants, supporting the therapeutic concept.
A handful of patients receiving the highest dose exhibited unexpected findings that raise questions and will be examined further.
The company said it will continue development and expand the trial to confirm these observations.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Astellas touts data from early test of stem cell-derived eye therapy”
read at Endpoints ↗83 words · retrieved May 8
comments(0)
5-min edit window · permanent after that